The ban on the drugs comes into immediate effect and the ministry has come out with a gazette notification regarding the matter.
"Altogether 344 such fixed dose combinations have been banned. We have tried to bring objectivity to the issue by roping in the best of scientists to study the effects.
"Show cause notices were also issued to more than 344 companies and they were given time to make further representations after the expert committee gave their recommendations," a senior Health Ministry official said.
According to the notification, the matter has been examined by an expert committee appointed by the Central government.
"On the basis of recommendations of the said expert committee, the Central government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drugs in the country," the notification said.
The 344 banned drugs include the fixed dose combination of Chlopheniramine Maleate and Codeine syrup sold under the popular cough syrup brand Corex.
"This is to inform you that the Government of India vide notification...Dated March 10, 2016...Has prohibited the manufacture for sale, sale and distribution of fixed dose combination of Chlopheniramine Maleate + Codeine Syrup with immediate effect.
"In view of this, the company has discontinued the manufacture and sale of its drug Corex with immediate effect," Pfizer said in a BSE filing today.
Fixed dose combination drugs are combinations of two or more active drugs in a single dose form.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
